BiondVax Pharmaceuticals Ltd. (BVXV) |
| 1.36 0.01 (0.74%) 09-06 15:59 |
| Open: | 1.32 |
| High: | 1.36 |
| Low: | 1.31 |
| Volume: | 22,668 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.58 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.92 |
| Resistance 1: | 0.81 |
| Pivot price: | 0.69 |
| Support 1: | 0.62 |
| Support 2: | 0.52 |
| 52w High: | 11.49 |
| 52w Low: | 0.63 |
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Financials
| EPS | -2.350 |
| Book Value | -1.960 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -30.9 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 25 Aug 2023
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17 - FinancialContent
Fri, 18 Aug 2023
Daily News - FinancialContent
Wed, 02 Aug 2023
Daily News - FinancialContent
Fri, 28 Jul 2023
Upcoming Events - FinancialContent
Fri, 24 Mar 2023
How to contact the Daily Bulletin - FinancialContent
Thu, 16 Mar 2023
How to contact the Daily Bulletin - FinancialContent
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
